YAP1 and mesothelioma: The purpose of that study is to characterize the safety and tolerability of IAG933 in patients with mesothelioma, NF2/LATS1/LATS2-mutated tumors and tumors with functional YAP1/TAZ fusions, as well as to identify the maximum tolerated dose.